Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Hold” from Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has earned an average recommendation of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $7.30.

ESPR has been the topic of several recent analyst reports. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Friday. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Institutional Trading of Esperion Therapeutics

A number of hedge funds have recently bought and sold shares of ESPR. Bank of New York Mellon Corp raised its position in shares of Esperion Therapeutics by 3,278.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after acquiring an additional 555,382 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Esperion Therapeutics by 6,560.6% during the second quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock valued at $560,000 after buying an additional 248,254 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of Esperion Therapeutics in the 2nd quarter worth approximately $50,000. Finally, BOKF NA bought a new position in shares of Esperion Therapeutics during the 2nd quarter worth approximately $26,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Up 7.8 %

ESPR stock opened at $2.34 on Friday. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94. The firm has a market cap of $461.07 million, a price-to-earnings ratio of -3.66 and a beta of 1.01. The business’s fifty day simple moving average is $2.46 and its two-hundred day simple moving average is $2.18.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.